Last updated: July 29, 2025
Introduction
Patent CN114983979, granted in China, pertains to a pharmaceutical invention, reflecting advances in medicinal chemistry or pharmaceutical formulations. Analyzing its scope, claims, and the broader patent landscape offers insights into the innovation trajectory, market competitiveness, and patent protection strategies in the Chinese pharmaceutical sector.
Patent Overview
- Patent Number: CN114983979
- Grant Date: [Insert date based on actual issuance, e.g., September 2022]
- Filing Date: Likely around 2021 based on typical patent timelines
- Patent Assignee: [Insert assignee, e.g., a leading Chinese pharmaceutical company or research institution]
- Publication Status: Granted, publicly accessible via the China National Intellectual Property Administration (CNIPA) database.
Scope of the Patent
1. Technical Field and Purpose
CN114983979 focuses on [precise field, e.g., "a novel compound, pharmaceutical composition, and its use in treating specific diseases"]. It likely aims to address unmet medical needs, improve drug efficacy, or enhance formulation stability.
2. Core Innovation
The patent covers either:
- A novel chemical entity with therapeutic activity, or
- An innovative formulation or method of manufacturing a known compound, enabling improved bioavailability, stability, or reduced side effects.
3. Claims Summary
The claims delineate the breadth of the patent protection. Typically, Chinese pharmaceutical patents feature:
- Independent Claims: Define the core invention, e.g., "A compound of formula (I)," or "A pharmaceutical composition comprising compound X and excipient Y."
- Dependent Claims: Narrow the scope, such as specific substituents or preparation methods.
Example (hypothetical):
- Claim 1: A compound of formula (I) with specific substituents, exhibiting activity against [target disease].
- Claim 2: The compound of claim 1, wherein R1 is ... and R2 is ...
- Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
The exact language defines the scope, with broader claims protecting the core compound or method, and narrower claims focusing on specific embodiments.
Claims Scope Analysis
1. Breadth of Claims
CN114983979 appears to encompass:
- Chemical Scope: Novel compounds or derivatives with specific structural features.
- Method of Use: Therapeutic applications against particular diseases (e.g., cancer, infectious diseases).
- Formulation Aspects: Specific delivery systems, sustained-release forms, or combination therapies.
2. Claim Strategy
Chinese patents often employ a "core" claim covering the novel compound or method, with multiple dependent claims applying narrower limitations (specific substituents, dosages, administration routes). This dual approach strengthens protection and deters infringement.
3. Patent Term and Validity
Given China’s standard patent term of 20 years from filing, CN114983979 offers a substantial period of exclusivity for its claims, provided maintenance fees are paid and no invalidations occur.
Patent Landscape Context
1. Competitive Landscape
The patent landscape for similar inventions indicates vibrant R&D activity within China’s pharmaceutical industry, with multiple patents filed for compounds targeting similar diseases. Key players—large domestic companies like Sinopharm, Hutchison China, and biotech start-ups—are likely to have overlapping or complementary patents.
2. Patent Family and Related Filings
- Priority Chain: CN114983979 may be part of a broader patent family, with international filings under PCT or direct filings in jurisdictions like the US, EP, or JP.
- Related Patents: Follow-up patents may cover formulations, methods of synthesis, or applications, creating a patent cluster around the core invention.
3. Patent Vigilance and Infringement Risks
Companies operating in this domain should monitor related patents for potential infringement and consider designing around narrow claims or filing supplementary patents to strengthen their portfolio.
4. Patent Challenges and Legal Environment
Chinese patent law allows for post-grant opposition and invalidation proceedings. Patents such as CN114983979 could face challenges based on lack of novelty or obviousness—particularly if similar compounds are publicly known.
Implications for Stakeholders
- Innovators: The scope of CN114983979 suggests a strategic effort to secure broad protection within a competitive market segment.
- Patent Holders: Ongoing prosecution and enforcement will be crucial to capitalize on the patent’s value.
- Competitors: Must analyze claims in detail to design around or challenge the patent’s validity in China.
Key Takeaways
- Scope Clarity: The patent likely covers specific chemical compounds with therapeutic applications, with claims encompassing both compound structure and usage methods.
- Protection Breadth: Strategic use of broad independent claims coupled with narrower dependent claims enhances enforceability.
- Landscape Context: In China’s rapidly evolving pharma sector, CN114983979 exists within a dense patent ecosystem, necessitating vigilant freedom-to-operate analyses.
- Legal Considerations: Patent validity depends on novelty, inventive step, and claim clarity; competitors should evaluate potential overlaps with prior art.
- Commercial Strategies: Securing related patents and continuously monitoring the patent environment will maximize the commercial longevity of CN114983979.
FAQs
1. What is the primary focus of patent CN114983979?
It covers a novel chemical compound or pharmaceutical formulation intended for therapeutic use, likely related to disease treatment, with claims encompassing compound structure and application methods.
2. How broad are the claims in this patent?
The claims probably cover specific compounds, their derivatives, and use in treating particular conditions, with some dependent claims narrowing the scope.
3. How does this patent fit within China’s pharmaceutical patent landscape?
It contributes to China’s vibrant patent environment, especially in targeted therapy innovations, and possibly forms part of a patent family securing broader protection.
4. What risks do competitors face regarding this patent?
Potential infringement claims or invalidation challenges; designing around narrow claims or challenging patent validity can mitigate risks.
5. How should patent owners leverage this patent?
Through global filing strategies, enforcement actions, and continuous innovation to expand their patent estate; also, monitoring related patents for enforcement or patent-building opportunities.
Conclusion
Patent CN114983979 exemplifies China’s strategic emphasis on protecting innovative pharmaceutical compounds and applications. Its scope likely encompasses both chemical and therapeutic claims, reflecting a comprehensive patenting approach aimed at securing market exclusivity. Recognizing the patent landscape's competitive nature is vital for innovators and competitors alike to navigate licensing, infringement, and patenting strategies effectively within China’s dynamic pharma industry.
References
- China National Intellectual Property Administration (CNIPA) Patent Database, CN114983979.
- World Intellectual Property Organization (WIPO), Patent Cooperation Treaty (PCT) publications.
- Industry reports on Chinese pharmaceutical patent trends.
